CompletedEarly Phase 1

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

United States1 participantsStarted 2014-01-21

Plain-language summary

This pilot trial studies propranolol hydrochloride in treating patients with locally recurrent or metastatic solid tumors that cannot be removed by surgery. Propranolol hydrochloride may slow the growth of tumor cells by blocking the use of hormones by the tumor cells.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Pathologically (histologically or cytologically) proven diagnosis of HCC.
✓. At least one solid liver lesion or vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) \> 1 cm with arterial enhancement and delayed washout on multiphasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis.
✓. For patients whose CURRENT disease is vascular only: Enhancing vascular thrombosis (involving portal vein, IVC and/or hepatic vein) demonstrating early arterial enhancement and delayed washout on multi-phasic CT or MRI, in a patient with known HCC (diagnosed according to criteria in (a) or (b).

What they're measuring

Incidence of toxicity graded according to Common Terminology Criteria for Adverse Events (CTCAE) V. 4.0

Timeframe: Up to 4 months

Change in vascular endothelial growth factor (VEGF)

Timeframe: Baseline to 4 months

Effect of beta-adrenergic blockade on the tumor microenvironment

Timeframe: Up to 4 months

Effect of beta-adrenergic blockade on the host immune system

Timeframe: Up to 4 months

Trial details

NCT IDNCT02013492

SponsorWilliam Carson

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-06-12

View on ClinicalTrials.gov More Male Breast Cancer trials